# US 2017/0285029 A1 · Immunohistochemistry scoring methods and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285029 A1
- Document ID: US20170285029A1
- Status: Published application
- Kind: A1
- Application number: 15/423,435
- Filed: 2017-02-02
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Agilent Technologies, Inc.
- Applicants: Agilent Technologies, Inc.
- Inventors: Debra Hanks; Mai Nguyen; Marko Srdanov; Che Hutson
- Web page: https://patentgrep.com/patent/US20170285029A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G01N 2333/70517: CD8
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent. In certain embodiments, the method includes determining, by immunohistochemistry, the number of PD-L1 positive malignant cells in a tumor tissue section as well as the number of infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area. The infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area are positive for a marker selected from PD-L1, CD8, CD68, and any combination thereof. Compositions and kits or performing the disclosed methods are also provided.

## Claims

### Claim 1

A method for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, the method comprising:
determining the percentage PD-L1 positive malignant cells (MC) per total malignant cells (TMC) (% MC/TMC) in a tumor tissue section from the subject;
determining a second parameter of a tumor tissue section from the subject, wherein the second parameter is selected from:
(i) the percentage of infiltrating non-malignant cells (I-NMC) per TMC (% I-NMC/TMC); and
(ii) the percentage of non-malignant cells of the stromal interface area (NMC-SIA) per TMC (% NMC-SIA/TMC);
wherein the I-NMC and NMC-SIA are positive for a marker selected from: PD-L1, CD8, CD68, and any combination thereof;
wherein the subject is eligible for treatment with an anti-PD therapeutic agent when the ratio of % MC/TMC is greater than 1%.

### Claim 2 (depends on 1)

The method of claim 1, wherein both the % I-NMC/TMC and % NMC-SIA/TMC are determined.

### Claim 3 (depends on 1)

The method of claim 1, wherein the I-NMC are positive for PD-L1, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % I-NMC/TMC is greater than 0 alone, or greater than or equal to % MC/TMC.

### Claim 4 (depends on 1)

The method of claim 1, wherein the I-NMC are positive for CD8, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % I-NMC/TMC is greater than 0 alone, or greater than or equal to % MC/TMC.

### Claim 5 (depends on 1)

The method of claim 1, wherein the I-NMC are positive for CD68, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % I-NMC/TMC is greater than 0 alone, or greater than or equal to % MC/TMC.

### Claim 6 (depends on 1)

The method of claim 1, wherein the NMC-SIA are positive for PD-L1, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % NMC-SIA/TMC is: greater than 5%; greater than % MC/TMC; and/or greater than % I-NMC/TMC.

### Claim 7 (depends on 1)

The method of claim 1, wherein the NMC-SIA are positive for CD8, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % NMC-SIA/TMC is: greater than 5%; greater than % MC/TMC; and/or greater than % I-NMC/TMC.

### Claim 8 (depends on 1)

The method of claim 1, wherein the NMC-SIA are positive for CD68, wherein the subject is eligible for treatment with an anti-PD therapeutic agent when % NMC-SIA/TMC is: greater than 5%; greater than % MC/TMC; and/or greater than % I-NMC/TMC.

### Claim 9 (depends on 1)

The method of claim 1, wherein the PD-L1, CD8 and/or CD68 markers are determined by immunohistochemistry (IHC) staining.

### Claim 10 (depends on 9)

The method of claim 9, wherein the IHC staining for each of PD-L1, CD8 and/or CD68 is performed on the same tissue section.

### Claim 11 (depends on 9)

The method of claim 9, wherein the IHC staining for each of PD-L1, CD8 and/or CD68 is performed on separate tissue sections of a single tumor biopsy sample from the subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the tumor tissue section is a formalin fixed and embedded in paraffin wax (FFPE) tumor tissue section.

### Claim 13 (depends on 1)

The method of claim 1, wherein the malignancy is selected from the group consisting of: renal cell carcinoma, urothelial carcinoma, ovarian carcinoma, myeloma, melanoma, lung cancer, squamous cell carcinoma, gastric cancer, bladder cancer, head and neck cancer, classical Hodgkin's lymphoma, Merkel cell carcinoma, and breast cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the % MC/TMC score is greater than 1%, and % iNMC/TMC and/or % NMC-SIA/TMC is positive.

### Claim 15 (depends on 14)

The method of claim 14, wherein the iNMC and NMC-SIA are CD8+ or CD68+.

### Claim 16 (depends on 13)

The method of claim 13, wherein the cancer is urothelial carcinoma.

### Claim 17 (depends on 13)

The method of claim 13, wherein the % MC/TMC score is 0, and % iNMC/TMC and/or % NMC-SIA/TMC is positive.

### Claim 18 (depends on 1)

The method of claim 1, wherein the anti-PD therapeutic agent comprises an anti-PD or anti-PD-L1 specific antibody or binding fragment thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the anti-PD therapeutic agent is selected from the group consisting of: Avelumab (MSB0010178C), Nivolumab, Pembrolizumab, BMS-936559, MPDL3280A, Pidilizumab, and MEDI4736.

### Claim 20

A kit for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, comprising:
a detectable PD-L1 specific binding agent;
a detectable CD8 specific binding agent;
a detectable CD68 specific binding agent; and
one or more reagents for performing an immunohistochemistry (IHC) staining reaction on a tumor tissue sample from a subject.
